Hypertension optimal treatment: the Israeli HOT Study Group. Hypertension Optimal Treatment.
A total of 411 patients were recruited in the Israeli cohort of the Hypertension Optimal Treatment (HOT) Study, a multinational study conducted to assess the effect on cardiovascular morbidity and mortality in hypertensive patients of three levels of target diastolic blood pressure: < 90, < 85, and < 80 mm Hg. Initial treatment with felodipine in all patients was supplemented with other drugs as needed. When compared to the subjects in the rest of the world, the percentage of Israeli patients getting previous antihypertensive treatment was higher, reflecting a higher proportion of hospital-recruited patients. This accounted for the lower percentage of Israeli patients ending up with low-dose felodipine: 50% vs 56% in other countries. The percentage of patients getting high-dose felodipine plus additional drugs was also higher: 3.8% vs 2.9% for other countries. Felodipine was remarkably well tolerated, and most of the patients were able to continue this drug regimen.
Rosenthal
T
T
Chorley Institute of Hypertension, Chaim Sheba Medical Center, Israel.
D000368:Aged; D000369:Aged, 80 and over; D000959:Antihypertensive Agents / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D015736:Felodipine / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000453:epidemiology / Q000401:mortality; D007391:International Cooperation; D008297:Male; D008875:Middle Aged; D009017:Morbidity; D011446:Prospective Studies
D000959:Antihypertensive Agents; D015736:Felodipine